moneyheap
CRSP · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is CRISPR Therapeutics AG (CRSP) stock moving?
The Nov 9 CTX310 Phase 1b data (65% ANGPTL3 and 63% triglyceride reduction, no treatment-related serious adverse events) and the Nov 8-9 zugo-cel autoimmune updates are the strongest clinical news in the set, and the company also has FDA RMAT designations for CTX310 from Nov 2. Yet the stock closed at $45.15 on Nov 10, down about 9.8% from $50.04 on volume of 4.0M, roughly 3x the typical ~1.2M, and near the 30-day low of $44.99. The provided news does not explain this sell-off, so the data may have been sold into, or the move may reflect factors outside these sources. Fundamentals are mixed: Q3 CASGEVY revenue reached $99M (up 30% quarter over quarter), but EPS of $(1.15) missed the $(0.98) estimate. Analysts remain constructive but diverge: Citigroup (Buy, $90 target) and Needham (Buy, $82 target) are above the current price, while Wells Fargo (Equal-Weight) cut its target to $70. Upcoming catalysts include the Jefferies conference on Nov 17, the ASH and ACR presentations, and the AHA late-breaker, and management changes (CFO promoted Oct 19, new CTO Nov 2) add some execution-continuity context. Risks include early-stage, small-sample Phase 1 and 1b data and the unexplained recent selling pressure.
News behind the analysis
- CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing TherapyPhase 1b data for CTX310 showed a 63% triglyceride drop and solid safety in severe hypertriglyceridemia.
- CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceSenior management will hold a fireside chat at the Jefferies Global Healthcare Conference on November 17, 2026.
- CRISPR Therapeutics Presents Positive Phase 1b Clinical Data for CTX310Phase 1b data for CTX310 showed significant reductions in ANGPTL3 and triglyceride levels in severe hypertriglyceridemia patients.
- CRISPR Therapeutics Reports 65% ANGPTL3 And 63% Triglyceride Reductions With CTX310 In Phase 1b Trial For Severe Hypertriglyceridemia; Well Tolerated, With No Treatment-Related Serious Adverse Events And No Clinically Relevant Elevations In Liver TransaminasesCTX310 cut ANGPTL3 by 65% and triglycerides by 63% with no treatment-related serious adverse events and no clinically relevant liver enzyme elevations.
- Reported Sunday, CRISPR Therapeutics Reports 83% Of Systemic Sclerosis Patients Achieved rCRISS-25 Response At Month 3 With Zugo-Cel, As All Nine Myositis Patients Achieve Moderate Or Major TIS Response83% of systemic sclerosis patients reached an rCRISS-25 response at month 3 on zugo-cel, and all nine myositis patients reached a moderate or major TIS response.
- CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune DiseasesPreliminary Phase 1 data for the allogeneic CAR-T therapy zugo-cel was released in refractory rheumatologic autoimmune diseases.
- Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90Citigroup kept its Buy rating and raised its price target to $90.
- Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70Wells Fargo kept its Equal-Weight rating and cut its price target to $70.
- CRISPR Therapeutics Says CASGEVY Q3 Revenue Of $99M Up 30% From Prior Quarter; More Than 750 Patients Have Initiated TreatmentCASGEVY generated $99M of Q3 2026 revenue, up 30% quarter over quarter and nearly six times Q3 2025, with more than 750 patients started on treatment.
- CRISPR Therapeutics Q3 EPS $(1.15) Misses $(0.98) Estimate, Sales $12.669M Beat $10.495M EstimateQ3 loss per share of $1.15 missed the $0.98 estimate, while sales of $12.67M beat the $10.50M estimate.
About CRISPR Therapeutics AG
CRISPR Therapeutics is a Swiss-domiciled biotech company, run from Zug and Boston, that uses CRISPR/Cas9 gene editing to develop medicines for serious diseases. It co-developed CASGEVY with Vertex Pharmaceuticals. CASGEVY treats sickle cell disease and beta-thalassemia and was the first approved CRISPR-based therapy.
How it makes money
Most of its value is tied to CASGEVY. Vertex leads the drug's commercialization, and CRISPR shares in its profits and costs through a collaboration that splits them roughly 40% to CRISPR and 60% to Vertex. Sales of CASGEVY were about $99 million in Q3 2026, up about 30% from the prior quarter. The company also earns some collaboration and licensing income. It still loses money, funding research from a cash pile of about $2.3 billion (as of September 2026) that it has topped up with stock and convertible-debt sales.
What usually moves CRSP
- Pace of CASGEVY patient starts and sales growth
- Clinical data from pipeline programs (zugo-cel CAR-T for autoimmune disease and cancer, CTX310 for heart disease, Factor XI siRNA)
- Regulatory decisions, such as expanding CASGEVY to younger patients
- Cash burn and dilution from stock or convertible-debt sales
- Sentiment toward gene-editing and biotech stocks broadly